NCT06972615View on ClinicalTrials.gov

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive to BCG Therapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

June 15, 2030

Conditions

Non Muscle Invasive Bladder Cancer

Interventions

DRUG

intravesical Chemotherapy docetaxel/gemcitabine

intravesical quimiotherapy plus intravenous immunotherapy

Trial Locations (1)

1123

BLATAM, CABA

All Listed Sponsors

lead

BLATAM

NETWORK